Country, language and currency
- Social bookmarks:
- Testimonials
-
Read more »
Our billing is certified by:
-
- Merck Wins U.S. ZETIA(R) (ezetimibe)/ VYTORIN(R) (ezetimibe/simvastatin ... - MarketWatch (press release)
- Merck Wins U
- Merck wins patent fight on Zetia, Vytorin; Fitch warns of 'pure pharma' risks; - FiercePharma
- Merck wins patent fight on Zetia, Vytorin; Fitch warns of 'pure pharma' risks;FiercePharmaArticle | Follow @FiercePharma > A US court upheld Merck's ($MRK) patent on the active ingredient ezetimibe, marketed as the cholesterol-lowering Zetia and in the combo cholesterol pill Vytorin
- Investor Medical Waves - (VVUS, MRK, MYL, AMPE) - Galaxy Stocks
- Investor Medical Waves - (VVUS, MRK, MYL, AMPE)Galaxy StocksInc
- Advanced Atherosclerosis: The Heart and Beyond - Medscape
- Advanced Atherosclerosis: The Heart and BeyondMedscapeThe premise of AIM-HIGH was to see if adding extended-release niacin to raise HDL cholesterol in patients who had already achieved a very low LDL cholesterol level (40 to 80 mg/dL) with simvastatin (and ezetimibe if needed) would lead to further risk
- Toward Regenerative Medicine Against Atherosclerosis cardiovascular disease - Next Big Future
- Toward Regenerative Medicine Against Atherosclerosis cardiovascular diseaseNext Big FutureOnce-promizing agents such as ezetimibe, niacin, ApoA-1 Milano, and torcetrapib have either been found to provide no benefit, or evento increase mortality rates
